Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 10:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 20,633 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Blood Clear all
Completed Phase 3 Interventional Results available

Safety and Effectiveness of Granulocyte Transfusions in Resolving Infection in People With Neutropenia (The RING Study)

NCT00627393
View directory record Official record
Conditions
Neutropenia, Infection
Interventions
Standard antimicrobial therapy, Granulocyte transfusions, G-CSF/dexamethasone, Apheresis machine
Drug · Biological · Device
Lead sponsor
Carelon Research
Other
Eligibility
Not listed
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
13
States / cities
Iowa City, Iowa • Baltimore, Maryland • Boston, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2015 · Synced Oct 19, 2026, 10:29 AM EDT
Withdrawn Phase 2 Interventional

Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer

NCT04965714
View directory record Official record
Conditions
Resectable Hepatocellular Carcinoma
Interventions
Nivolumab, Pegargiminase, Resection
Biological · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Oct 19, 2026, 10:29 AM EDT
Recruiting Phase 3 Interventional

Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemotherapy

NCT06763328
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Invasive Breast Carcinoma
Interventions
Biospecimen Collection, Educational Intervention, Extended Release Metformin Hydrochloride, Questionnaire Administration
Procedure · Other · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
3
States / cities
Duarte, California • La Jolla, California • Riverside, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 19, 2026, 10:29 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis

NCT02850965
View directory record Official record
Conditions
Psoriasis
Interventions
BI 695501, Humira
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
14
States / cities
Anniston, Alabama • Phoenix, Arizona • Santa Ana, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2019 · Synced Oct 19, 2026, 10:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Alinity s Anti-HCV II - Clinical Evaluation Protocol

NCT04862065
View directory record Official record
Conditions
Healthy
Interventions
Alinity s Anti-HCV II
Device
Lead sponsor
Abbott Transfusion Medicine
Industry
Eligibility
18 Years and older
Enrollment
16,388 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
4
States / cities
Saint Paul, Minnesota • Knoxville, Tennessee • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2022 · Synced Oct 19, 2026, 10:29 AM EDT
Terminated Phase 1 Interventional

Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

NCT00003567
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
filgrastim, sargramostim, therapeutic autologous lymphocytes, O6-benzylguanine, carmustine, temozolomide, in vitro-treated peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 11, 2010 · Synced Oct 19, 2026, 10:29 AM EDT
Completed Phase 2Phase 3 Interventional

Does BRV Have Faster Onset Time & Greater Effect Than LEV in Epilepsy Pts Using PPR Pharmacodynamic Efficacy Endpoint

NCT03580707
View directory record Official record
Conditions
Photosensitive Epilepsy
Interventions
BRV vs LEV in randomized double blinded, crossover fashion
Drug
Lead sponsor
Rosenfeld, William E., M.D.
Individual
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Oct 19, 2026, 10:29 AM EDT
Completed Phase 1 Interventional

Convalescent Plasma for the Treatment of COVID-19 (Coronavirus Disease 2019)

NCT04554992
View directory record Official record
Conditions
Covid19
Interventions
COVID 19 Convalescent Plasma
Biological
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 19, 2026, 10:29 AM EDT
Completed Not applicable Interventional Results available

Point-of-Care Glucose Testing and Insulin Supplementation

NCT01702311
View directory record Official record
Conditions
Diabetes
Interventions
Bedtime insulin Aspart (Novolog)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 3, 2018 · Synced Oct 19, 2026, 10:29 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis

NCT04186871
View directory record Official record
Conditions
Autoimmune Disorder, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Primary Sjögren's Syndrome
Interventions
branebrutinib, abatacept, branebrutinib placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
40
States / cities
Phoenix, Arizona • Covina, California • Encino, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Oct 19, 2026, 10:29 AM EDT
Terminated Phase 2 Interventional Results available

Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer

NCT01871571
View directory record Official record
Conditions
Mucinous Adenocarcinoma of the Rectum, Signet Ring Adenocarcinoma of the Rectum, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Rectal Cancer, Stage IIIC Rectal Cancer
Interventions
bevacizumab, oxaliplatin, leucovorin calcium, fluorouracil, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 19, 2026, 10:29 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Vallania Study: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening

NCT05254834
View directory record Official record
Conditions
Cancer
Interventions
Freenome Test
Diagnostic Test
Lead sponsor
Freenome Holdings Inc.
Industry
Eligibility
30 Years and older
Enrollment
7,435 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
68
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Springdale, Arkansas + 62 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 19, 2026, 10:29 AM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel

NCT02073487
View directory record Official record
Conditions
Breast Cancer
Interventions
T-DM1, Trastuzumab, Lapatinib, Abraxane, Paclitaxel, Pertuzumab
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
3
States / cities
Houston, Texas • Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Oct 19, 2026, 10:29 AM EDT
Recruiting Phase 1 Interventional

ABY-029 Glioma Trial

NCT07063693
View directory record Official record
Conditions
Intracranial Tumor
Interventions
ABY-029
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 19, 2026, 10:29 AM EDT
Completed Phase 2 Interventional

A Study of Abicipar Pegol in Patients With Diabetic Macular Edema

NCT02186119
View directory record Official record
Conditions
Macular Edema
Interventions
abicipar pegol, ranibizumab, sham procedure
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
19 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Gilbert, Arizona • Abilene, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2015 · Synced Oct 19, 2026, 10:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Two-part Trial Assessing the Effects of 7α-methyl-19-nortestosterone (MENT) on Blood Pressure in Normal Men: an Open-label Pilot Study Followed by a Randomized, Double-blind, Placebo-controlled Study

NCT00812630
View directory record Official record
Conditions
Blood Pressure
Interventions
MENT or placebo
Drug
Lead sponsor
Population Council
Other
Eligibility
18 Years to 40 Years · Male only
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 15, 2017 · Synced Oct 19, 2026, 10:29 AM EDT
Terminated Phase 1 Interventional

L-asparaginase Encapsulated in Red Blood Cells (Eryaspase) for Treatment of Adult Patients With ALL or LBL

NCT01910428
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Interventions
L-asparaginase encapsulated in RBC
Drug
Lead sponsor
ERYtech Pharma
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
5
States / cities
Chicago, Illinois • Baltimore, Maryland • Lake Success, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 19, 2026, 10:29 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Release Kinetics of rhBMP-2 Using E-PRF as an Autologous Carrier: An In Vitro Analysis

NCT04670965
View directory record Official record
Conditions
Bone Loss
Interventions
E-PRF/rhBMP-2 (similar ratios), E-PRF/ACS/rhBMP-2, rhBMP-2/E-PRF, E-PRF only
Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 19, 2026, 10:29 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation

NCT01966367
View directory record Official record
Conditions
Bone Marrow Failure Syndrome, Severe Aplastic Anemia, Severe Congenital Neutropenia, Amegakaryocytic Thrombocytopenia, Diamond-Blackfan Anemia, Schwachman Diamond Syndrome, Primary Immunodeficiency Syndromes, Acquired Immunodeficiency Syndromes, Histiocytic Syndrome, Familial Hemophagocytic Lymphocytosis, Lymphohistiocytosis, Macrophage Activation Syndrome, Langerhans Cell Histiocytosis (LCH), Hemoglobinopathies, Sickle Cell Disease, Sickle Cell-beta-thalassemia
Interventions
CD34 Stem Cell Selection Therapy
Biological
Lead sponsor
Diane George
Other
Eligibility
Up to 40 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 19, 2026, 10:29 AM EDT
Completed No phase listed Observational Results available

Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma

NCT05105100
View directory record Official record
Conditions
Melanoma, Advanced Melanoma
Interventions
Biopsy, Biospecimen Collection
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 19, 2026, 10:29 AM EDT
Completed No phase listed Observational

Functional Imaging in Lung SBRT

NCT03121300
View directory record Official record
Conditions
Lung Cancer
Interventions
CT Scan, Lung CT, MRI, Walk Test, SGRQ, Biological Sample Collection, Toxicity, Cardiac Assessment
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 17, 2019 · Synced Oct 19, 2026, 10:29 AM EDT
Recruiting Phase 1Phase 2 Interventional

Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas

NCT07468136
View directory record Official record
Conditions
Anaplastic Oligodendroglioma, Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4, Diffuse Astrocytoma, Glioblastoma, IDH-Wildtype, Malignant Glioma
Interventions
Biospecimen Collection, Eflornithine, Lumbar Puncture, Magnetic Resonance Imaging, Retifanlimab, Tumor Resection
Procedure · Drug · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 19, 2026, 10:29 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

PET Scans in Normal Volunteers and Patients With Fabry Disease

NCT00005111
View directory record Official record
Conditions
Fabry Disease, Healthy
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 19, 2026, 10:29 AM EDT
Terminated Phase 1 Interventional Results available

A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer

NCT00779311
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
sorafenib, bevacizumab, mFOLFOX6 regimen
Drug
Lead sponsor
Accelerated Community Oncology Research Network
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
3
States / cities
Macon, Georgia • Billings, Montana • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 2, 2011 · Synced Oct 19, 2026, 10:29 AM EDT